<DOC>
	<DOCNO>NCT01505426</DOCNO>
	<brief_summary>To compare efficacy safety ASP1941 + metformin metformin alone Asian subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>A Study Assess Efficacy Safety ASP1941 Combination With Metformin Asian Diabetes Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Diagnosed type 2 diabetes mellitus patient least 12 week study Stable diet exercise program least 8 week study On stable dose least 1500 mg/day metformin monotherapy least 1000 mg/day metformin monotherapy subject titrate 1500 mg/day due safety concern metformin BMI 20.0 45.0 kg/m2 A HbA1c value 7.0 10.0 % screening AND meet discontinuation criterion fast plasma glucose Type 1 diabetes mellitus Proliferative diabetic retinopathy Receiving insulin within 12 week prior study History clinically significant renal disease ( ) Significant dysuria cause neurogenic bladder benign prostate hypertrophy etc . Urinary tract infection genital infection Continuous use systemic corticosteroid , immunosuppressant , loop diuretic History cerebrovascular attack , unstable angina , myocardial infarction , angioplasty , serious cardiac disease within 12 week prior study Severe infection , serious trauma , perioperative subject Known suspect hypersensitivity ASP1941 History treatment ASP1941 Participated another clinical study , postmarketing study medical device study within 12 week study Serum creatinine value exceed upper limit normal range Urinary microalbumin/urinary creatinine ratio &gt; 300 mg/g</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ASP1941</keyword>
	<keyword>ipragliflozin</keyword>
	<keyword>metformin</keyword>
	<keyword>plasma glucose</keyword>
	<keyword>urine glucose</keyword>
</DOC>